On April 15, CareDx agreed to divest its Lab Products business to EuroBio Scientific for $170 million in cash. The transaction has been approved by the boards of directors of both companies. The company also announced preliminary financial results for the first quarter alongside the divestiture.
Financial markets are maintaining strong momentum in capital-raising activities, highlighted by Trevi Therapeutics pricing its public offering of 11,600,000 shares at $13.00 per share. The company granted underwriters a 30-day option for an additional 1,740,000 shares, with the offering expected to close on April 20,…
Read the full storyCaris Life Sciences (NASDAQ: CAI) is expanding its 'Right-In-Time' (RIT) clinical trial solution to bridge the geographic gap in precision oncology access. The initiative addresses a critical disparity where 70% of U.S. counties currently lack active cancer treatment trials, impacting nearly 20% of Americans aged 55…
PDS Biotechnology has announced promising interim Phase 2 clinical trial data for its PDS01ADC treatment targeting metastatic colorectal cancer. The data, released in collaboration with the National Cancer Institute (NCI), revealed a significant 78% Objective Response Rate (ORR), substantially outperforming current…
ProPhase Labs reported its full-year 2025 financial results, revealing a substantial $201.2 million in gross medical claims. The company is currently engaged in active negotiations, targeting a net recovery of $50 million to $60 million to bolster its cash position. Management highlighted accelerating settlement…
Quanterix Corporation and Akoya Biosciences have debuted their joint Content Innovation Engine ahead of the AACR Annual Meeting 2026 in San Diego. This framework integrates SIMOA technology with spatial biology to offer researchers ultra-sensitive diagnostic insights into cancer hallmarks. Joining the high-profile…
PacBio and Covaris have announced a joint workflow designed to enable HiFi long-read sequencing of Formalin-Fixed Paraffin-Embedded (FFPE) tumor samples. This collaboration aims to significantly improve genetic data extraction from archived clinical samples, which are critical for cancer research. By combining…
Nkarta, Inc. has secured an agreement with the FDA to transition its NKX019 therapy to outpatient dosing, enhancing commercial viability and patient access. During the Needham Healthcare Conference, Artiva CEO Fred Aslan detailed the mechanism of action for the company's NK cell platform, emphasizing the strategic…
French company Eurobio Scientific has officially signed a definitive agreement to acquire CareDx's Lab Products division for $170 million in cash. The transaction has been approved by the boards of directors of both companies and is expected to close by the end of the third quarter of 2026. This acquisition is…